Morgan Stanley’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-34,783
| Closed | -$44.3K | – | 8049 |
|
|
2023
Q3 | $44.3K | Sell |
34,783
-8,831
| -20% | -$7.71K | ﹤0.01% | 6216 |
|
|
2023
Q2 | $14.2K | Hold |
43,614
| – | – | ﹤0.01% | 6678 |
|
|
2023
Q1 | $18.8K | Sell |
43,614
-4,005
| -8% | -$2.11K | ﹤0.01% | 6657 |
|
|
2022
Q4 | $25.2K | Buy |
47,619
+12,630
| +36% | +$8.01K | ﹤0.01% | 6582 |
|
|
2022
Q3 | $25K | Sell |
34,989
-1,271
| -4% | -$1.44K | ﹤0.01% | 6701 |
|
|
2022
Q2 | $41K | Sell |
36,260
-597
| -2% | -$760 | ﹤0.01% | 6698 |
|
|
2022
Q1 | $75K | Sell |
36,857
-61,941
| -63% | -$147K | ﹤0.01% | 6491 |
|
|
2021
Q4 | $284K | Sell |
98,798
-8,614
| -8% | -$31.9K | ﹤0.01% | 5875 |
|
|
2021
Q3 | $456K | Sell |
107,412
-170,281
| -61% | -$760K | ﹤0.01% | 5558 |
|
|
2021
Q2 | $1.47M | Buy |
277,693
+208,797
| +303% | +$1M | ﹤0.01% | 4855 |
|
|
2021
Q1 | $321K | Buy |
68,896
+54,787
| +388% | +$248K | ﹤0.01% | 5389 |
|
|
2020
Q4 | $47K | Sell |
14,109
-2,359
| -14% | -$8.96K | ﹤0.01% | 6180 |
|
|
2020
Q3 | $55K | Sell |
16,468
-7,697
| -32% | -$28.3K | ﹤0.01% | 5695 |
|
|
2020
Q2 | $81K | Sell |
24,165
-1,478
| -6% | -$6.99K | ﹤0.01% | 5499 |
|
|
2020
Q1 | $98K | Sell |
25,643
-420,982
| -94% | -$1.96M | ﹤0.01% | 5199 |
|
|
2019
Q4 | $2.7M | Buy |
446,625
+302,100
| +209% | +$2.07M | ﹤0.01% | 3796 |
|
|
2019
Q3 | $1.09M | Buy |
144,525
+15,756
| +12% | +$178K | ﹤0.01% | 4242 |
|
|
2019
Q2 | $1.75M | Buy |
128,769
+26,390
| +26% | +$305K | ﹤0.01% | 3878 |
|
|
2019
Q1 | $555K | Buy |
102,379
+93,014
| +993% | +$453K | ﹤0.01% | 4487 |
|
|
2018
Q4 | $28K | Sell |
9,365
-5,539
| -37% | -$30.3K | ﹤0.01% | 5943 |
|
|
2018
Q3 | $121K | Sell |
14,904
-51,885
| -78% | -$398K | ﹤0.01% | 5631 |
|
|
2018
Q2 | $651K | Buy |
66,789
+3,444
| +5% | +$35.3K | ﹤0.01% | 4919 |
|
|
2018
Q1 | $551K | Sell |
63,345
-186,695
| -75% | -$2.01M | ﹤0.01% | 4949 |
|
|
2017
Q4 | $3.13M | Buy |
250,040
+156,879
| +168% | +$1.8M | ﹤0.01% | 3602 |
|
|
2017
Q3 | $780K | Buy |
93,161
+54,219
| +139% | +$573K | ﹤0.01% | 4595 |
|
|
2017
Q2 | $660K | Sell |
38,942
-18,810
| -33% | -$374K | ﹤0.01% | 4633 |
|
|
2017
Q1 | $1.16M | Buy |
57,752
+39,722
| +220% | +$789K | ﹤0.01% | 4266 |
|
|
2016
Q4 | $281K | Buy |
18,030
+123
| +0.7% | +$1.66K | ﹤0.01% | 5211 |
|
|
2016
Q3 | $233K | Buy |
17,907
+7,768
| +77% | +$73.8K | ﹤0.01% | 4947 |
|
|
2016
Q2 | $70K | Buy |
10,139
+6,639
| +190% | +$55.6K | ﹤0.01% | 5402 |
|
|
2016
Q1 | $33K | Buy |
3,500
+134
| +4% | +$1.08K | ﹤0.01% | 5764 |
|
|
2015
Q4 | $34K | Sell |
3,366
-6,645
| -66% | -$87.9K | ﹤0.01% | 5860 |
|
|
2015
Q3 | $143K | Buy |
+10,011
| New | +$246K | ﹤0.01% | 5250 |
|
Morgan Stanley's ZYNE Position: Q4 2023 in Review
Morgan Stanley sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 34,783 shares — an estimated $44.3K sold.
Morgan Stanley first reported a position in ZYNE in Q3 2015 and held it in 33 quarters. The position peaked at $3.13M in Q4 2017. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Morgan Stanley reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 34,783 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $44.3K.
- Morgan Stanley first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 33 quarters.
- Morgan Stanley's Zynerba Pharmaceuticals, Inc position peaked at $3.13M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.